Sales rise offsets AstraZeneca profits

Pharmaceuticals giant AstraZeneca today overcame dismay at regulatory glitches for a key new drug by reporting a 7% hike in third-quarter sales.

AstraZeneca said it achieved turnover of $5.27bn (€4.2bn) despite weaker demand from American wholesalers who stockpiled medicines during the previous year.